Special Issue

Molecular Mechanisms in Anaphylaxis

Message from the Guest Editor

Anaphylaxis (AX) is the most severe manifestation of allergic disorders, being a systemic hypersensitivity life-threatening reaction that evolves rapidly. Among the most frequent triggers are food, drugs, and hymenoptera venoms. The plethora of features associated with AX confers difficulties in its diagnosis, impairing the ability to adequately treat these severe reactions. Generally, the diagnosis is carried out according to the clinical symptoms, which are common to many other pathologies, so confirmation through in vitro markers and knowledge about their molecular mechanisms is advisable. Mast cells and basophils are recognized as effector cells eliciting the anaphylactic reaction. However, many other cells and mediators are also relevant. Moreover, the release of mediators causes an endothelial barrier breakdown. This fact produces an increase in vascular permeability and a leakage of fluids, which have influence in two decisive and severe factors (hypotension and hypoxia). Thus, the primary purpose of this Special Issue is to collect scientific contributions providing novel insight into the molecular mechanisms of AX.

Guest Editor

Dr. Vanesa Esteban

1. Department of Allergy and Immunology, IIS-Fundación Jiménez Díaz, UAM, 28040 Madrid, Spain
2. Faculty of Medicine and Biomedicine, Alfonso X El Sabio University, 28691 Madrid, Spain

Deadline for manuscript submissions

closed (30 December 2022)

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/si/79755

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines

Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed

mdpi.com/journal/biomedicines

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).